It’s now 5 months because the German Federal Cupboard adopted draft amendments to its pivotal Medizinal-Cannabisgesetzes (MedCanG) invoice, and its finalisation is predicted within the coming weeks.
Since MedCanG was carried out alongside CanG in early 2024, Germany’s medical hashish market has grown at a fee that has stunned even its most bullish advocates. Imports practically tripled in 2025 alone, funding has flooded in, and North American operators have scrambled to safe a foothold in what’s now comfortably Europe’s largest regulated market.
The proposed amendments, which goal on-line prescriptions, mail-order supply, promoting practices, and international prescriptions, threaten to reshape the circumstances that drove that development. Whether or not the end result can be higher for sufferers, the trade, or each relies upon largely on who you ask.
The coalition authorities stays cut up on which measures to enact and to what extent, with the SPD and Greens pushing again exhausting in opposition to the invoice’s most restrictive parts. The ultimate regulation, when it comes, is more likely to look considerably completely different from what Well being Minister Nina Warken initially proposed.
For Cansativa, one among Europe’s largest pharmaceutical hashish distributors, a regulatory clampdown is in the very best pursuits of the trade in the long term.
Jakob Sons, who co-founded Cansativa alongside his brother Benedikt, informed Enterprise of Hashish: “Regulatory tightening advantages compliance-focused infrastructure suppliers. Increased enforcement requirements enhance obstacles to entry and strengthen aggressive moats.”
Enterprise Intelligence
Hashish M&A Tracker
A constantly up to date dataset monitoring mergers, acquisitions and main offers shaping the worldwide hashish trade since 2020.
Enterprise of Hashish Intelligence
Discover tracker →
The invoice and the fault strains
The draft modification, adopted by the Federal Cupboard in October 2025, was framed as a corrective to what Well being Minister Warken has described as ‘clear abuse’ of the framework.
This evaluation is predicated on assertions that medical hashish imports into Germany rose by over 400% year-on-year within the first half of 2025, however statutory medical health insurance prescriptions solely elevated modestly. The federal government’s conclusion, due to this fact, is that self-paying sufferers are utilizing the swathe of on-line prescription providers to acquire medical hashish for leisure functions.
To rectify this dynamic, the proposed amendments sought to impose requirement of necessary in-person session between physician and affected person earlier than any hashish prescription may be issued, ban mail-order supply of hashish flower by pharmacies, and introduce stricter promoting restrictions. A fourth measure, refusing to recognise international EU prescriptions in German pharmacies, was proposed by the Bundesrat however rejected by the federal authorities on EU regulation grounds.
The invoice acquired its first studying within the Bundestag in December, adopted by a public knowledgeable listening to within the Well being Committee in January. Whereas no selections had been made through the listening to, a consensus that telemedicine platforms, loosely regulated and susceptible to aggressive promoting, had been the important thing subject.
The promoting subject is already being examined within the courts. In January, the Frankfurt Regional Courtroom granted an injunction in opposition to telemedicine platform Bloomwell, prohibiting it from utilizing celeb endorsements, together with German rapper Sido, to promote medical hashish, and from providing free prescriptions as a purchase order incentive.
A broader case earlier than the Federal Courtroom of Justice, analyzing whether or not Bloomwell’s whole mannequin constitutes prohibited prescription drug promoting, stays pending.
Jakob Sons defined: “Telemedicine platforms contributed to short-term value compression by enabling aggressive bidding dynamics between producers looking for itemizing visibility. That dynamic created short-term distortion however not structural demand weak point. As regulatory tightening progresses, we count on equilibrium to return.”
Because the parliamentary debate continues over which proposals to push via, fault-lines seem to have hardened. The CDU/CSU wants SPD assist to go the invoice, however that assist is much from forthcoming.
SPD well being coverage knowledgeable Serdar Yüksel has warned that limiting telemedicine entry ‘will notably have an effect on individuals who can’t discover an skilled physician domestically,’ mentioning that many normal practitioners have restricted expertise with hashish, leaving specialist practices, typically working nationally through telemedicine, as the first level of care for a lot of sufferers.
His colleague Matthias Mieves added: “I don’t suppose a normal ban on the mail-order sale of medical hashish is the best method.”
In the meantime, the Greens have known as for a ‘standardised on-line prescribing system’ quite than prohibition, and have individually cited an knowledgeable opinion concluding that an outright ban on on-line prescribing violates EU regulation.
Notably, even inside CDU/CSU there may be reported inside disagreement, with well being spokesperson Simone Borchardt confirming the celebration is actively exploring compromise positions with its coalition companion.
As such, it’s unlikely the proposals will make it into regulation with out important concessions, if in any respect. The rising cross-party consensus factors towards necessary real medical session for preliminary prescriptions, with video session remaining permissible the place medically justifiable, alongside tighter documentation requirements and stricter promoting guidelines. The total telemedicine ban and the mail-order ban are each unlikely to be introduced ahead in any kind that resembles the preliminary proposals.
Jakob said: “We count on stronger enforcement round prescription integrity, telemedicine oversight and promoting guidelines for prescription medicines. Germany applies strict pharmaceutical promoting legal guidelines and medical hashish will more and more be handled constantly inside that framework. The path of journey is evident. Doctor oversight can be strengthened, pharmacy meting out will stay central and loosely regulated digital steering mechanisms will face tighter scrutiny.”
READ MORE…
What is going to it imply for the sector?
No matter kind the ultimate amendments take, Cansativa’s co-founders are assured on the place the market is heading and the way lengthy it should take to get there.
“For traders, regulatory readability reduces volatility,” Jakob continued. “A pharmacy-centred system with enforceable requirements creates long-term stability.”
That stability, in Cansativa’s view, is the precondition for Germany realising its full potential. As Benedikt Sons set out within the first a part of our interview, the corporate estimates Germany’s long-term annual market potential at roughly €8bn, with the broader European alternative exceeding €20 billion.
Reaching that scale, he argues, requires a number of structural shifts to happen in parallel. “Doctor training should proceed, reimbursement pathways ought to develop, and regulatory readability should stay constant,” he mentioned.
“Cross-border European harmonisation will additional speed up development. A sensible horizon for reaching that scale is 4 to seven years, assuming continued consolidation and regulatory stability.”
“Importantly, this projection displays not solely home demand however Germany’s position as Europe’s central distribution hub. Europe is early within the adoption curve, and medical hashish represents probably the most important rising healthcare segments on the continent.”
The latest wave of M&A exercise suggests the market is already organising itself round that thesis with out ready for legislative certainty. The caveat is {that a} softer legislative final result than Warken initially proposed would depart some platform-driven fashions extra intact than Cansativa’s thesis implies.
Jakob Sons believes that whatever the legislative final result, the path of journey is evident.
“Germany embedded medical hashish inside its pharmaceutical system from the outset. The important thing lesson is that infrastructure should scale alongside entry. Markets pushed primarily by digital channel arbitrage are unstable. Markets anchored in healthcare compliance are sturdy.”
The second and third Bundestag readings are anticipated within the coming weeks. No matter emerges, the trade is already looking forward to the subsequent section of the market.
